本研究分析了人乳头瘤病毒-6型L1外壳蛋白之B-细胞优势表位，并拟以此为基础制作表位多肽疫苗。研究中采用Goldkey和PC/Gene软件系统综合分析HPV6之L1蛋白B-细胞优势表位后，Fmoc固相合成表位多肽，通过HPLC纯化和毛细管电泳分析其纯度。与佐剂完全乳化后，免疫小鼠，进行动物水平的免疫效果评价。取免疫小鼠血清，与HPV-6 DNA阳性的尖锐湿疣患者疣体组织上清液结合，以鉴定免疫小鼠所产生抗体的特异性。发现L1蛋白第425-439位和第486-500位具有较高的免疫原性，可明显诱导小鼠血清抗体滴度升高，且该抗体与人尖锐湿疣疣体组织上清液呈阳性反应。说明所选这两个肽段为HPV6之L1蛋白的B-细胞优势表位，但诱导产生的抗体是否具有功能特异性，正在做进一步研究。

We analyzed and verificated the B-cell epitope of the L1 capsid protein of the Human papilloma virus type 6, and made it the base of producing new subunit peptide vaccine. Goldkey and PC/ Gene computer program were used to colligate and analyze the B-cell epitope of HPV6 L1. These peptides were synthesised and purified by Fmoc and HPLC methods, respectively. After that the peptides were emulsified with 0.2ml adjuvant, the blood serum antibody titer of mouse immuned by 50 μg peptides were detected. We found that, the B cell epitopes of the L1 protein of HPV-6 could be located at NO.425-439 and 486-500 positions. Those synthesized peptides have the ability to raise blood serum antibody titer enormously in vitro, and the antibody induced by these synthesized peptides could react with the supernatant of human papilloma tissue. We conclude that NO. 425-439 and 486-500 positions are predominat B-cell epitope of HPV 6 L1 protein. More work is under way to investigate whether these antibodies could perform functions.